News | November 18, 2022
Apollo launches national program to promote rational use of antibiotics
Program will fight the rising incidence of antimicrobial (drug) resistance and improve patient outcomes
Program will fight the rising incidence of antimicrobial (drug) resistance and improve patient outcomes
The TBDA is a collaboration established among biopharmaceutical companies, research organizations and universities to accelerate the discovery and development of novel therapeutic candidates against TB.
WCK 5222 is a Super-drug which is entirely a new class of antibiotic known as "?-lactam ENHANCER".
The USFDA has granted a qualified infectious disease product (QIDP) designation to WCK 6777, which signifies its ability to meet unmet medical needs and facilitates a faster approval process
The company to receive upfront and milestone payments, in addition to royalties
The products include high-quality, advanced anti-infective formulations such as EMROK (Levonadifloxacin) and MIQNAF (Nafithromycin)
Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach
The PLI scheme focuses on incentivizing a strategic shift towards high-value, innovative products such as biologics, complex generics, and specialty formulations
Reinforcing commitment to ethical and sustainable growth
The partnership aims to co-develop technologies set to revolutionize manufacturing of plasmid DNA (pDNA), a critical raw material for advanced medicines
Subscribe To Our Newsletter & Stay Updated
